Company news
Abvc Biopharma, Inc. (NASDAQ:ABVC) news
Abvc Biopharma, Inc. news releases on 6ix. Latest, Mar 14, 2024: ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter…
Press releases — page 2
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
March 13, 2024
ABVC BioPharma Executes a Definitive Agreement to Receive License Fees of $3M and Royalties of 2% on Future Revenues
February 14, 2024
ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)
February 11, 2024
ABVC BioPharma and its Subsidiary Receive $460M From AiBtl BioPharma as the First Milestone Payment of Global Licensing Fees
January 3, 2024
ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results
November 14, 2023
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
October 25, 2023
ABVC BioPharma Receives Taiwanese Patent for Its Treatment of Major Depressive Disorder (MDD)
October 8, 2023
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
August 22, 2023
ABVC Executes Cooperation Agreement for Strategic Investments
August 16, 2023
ABVC BioPharma Regains Compliance With Nasdaq's Minimum Bid Price Requirement
August 9, 2023
ABVC Corporate Update and CEO's Letter to Shareholders
August 6, 2023
ABVC Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration
August 2, 2023
ABVC Signs a Term Sheet to Earn Licensing Fees of up to $20M and Royalties of 5-12% of Net Sales
July 31, 2023
ABVC BioPharma Announces Closing on $1.75 Million Registered Direct Offering
July 30, 2023
ABVC BioPharma Announces Pricing of $1.75 Million Registered Direct Offering
July 26, 2023
ABVC Signs Term Sheet to Acquire Real Estate Assets for Strategic Investments
July 25, 2023
ABVC BioPharma Announces Reverse Stock Split
July 23, 2023
ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth
June 25, 2023
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
June 11, 2023
ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercialization
June 5, 2023
ABVC BioPharma Vitargus® Phase II Study Received Ethical Approval at Sydney Eye Hospital in Australia
May 21, 2023
ABVC BioPharma Receives US Patent Certificate of PDC-1421 for the Treatment of Major Depressive Disorder
May 3, 2023
ABVC BioPharma Announces Completion of Phase II Part 2 Clinical Study Site Initiation Visit at UCSF
April 25, 2023
ABVC BioPharma Provides ABV-1601 Update on Phase I Site Initiation Visit Conducted at Cedars-Sinai Medical Center (CSMC)
April 9, 2023
ABVC BioPharma Provides Vitargus Update on Phase II Site Initiation Visit Conducted at Ramathibodi Hospital in Thailand
April 5, 2023
ABVC BioPharma Announces Fiscal Year 2022 Financial and Operational Results
March 30, 2023
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare
March 13, 2023
ABVC BioPharma Provides 2023 Pipeline Update
February 27, 2023
ABVC BioPharma Receives Australian TGA Approval to Initiate Phase II Study of Vitargus®
February 20, 2023
ABVC BioPharma Provides Vitargus® Update - Phase II Vitargus® Study Protocol Received Thai FDA Approval
November 16, 2022
ABVC BioPharma Reports Third Quarter 2022 Financial and Operational Results
November 13, 2022
ABVC BioPharma Announces Vitargus® Phase II Study Plan Approved by HREC in Australia
October 4, 2022
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
September 22, 2022
ABVC Biopharma Announces Letter to Shareholders
September 12, 2022
ABVC BioPharma Selects Additional Vitargus® Phase II Study Site
September 8, 2022
ABVC BioPharma Reports Second Quarter 2022 Financial and Operational Results
August 14, 2022
ABVC BioPharma Provides Vitargus® Update
August 1, 2022
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
July 12, 2022
ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation
June 20, 2022
ABVC BioPharma Submitted Vitargus® Phase II Study Plan to Australia HREC
June 15, 2022
ABVC BioPharma Announces Termination of Two Contracts
June 9, 2022
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
May 31, 2022
ABVC Biopharma Reports First Quarter 2022 Financial and Operational Results
May 15, 2022
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding
May 12, 2022
ABVC BioPharma, Inc. Announces $4.22 Million Registered Direct Offering
May 11, 2022
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
May 9, 2022
ABVC BioPharma Announces Streamlined Vitargus® Manufacturing Process
May 4, 2022
ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed
May 2, 2022
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
April 27, 2022
ABVC BioPharma Announces Vitargus Phase II Clinical Study Investigator Meeting
April 25, 2022